BIOCAN NOVEL DHPPI-L4
MANUFACTURER: Bioveta
PRODUCT CATEGORY: Vaccines
COMPOSITION 1ml :
Lyophilisate
Canine Distemper virus, strain CDV Bio 11/A - min. 103.1 TCID50*, max. 105.1 TCID50*
Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50**, max. 105.3 TCID50*
Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - in. 104.3 TCID50*,max. 106.6 TCID50*
Canine Parainfluenza Type 2virus, strain CPiV-2 Bio 15 - min. 103.1 TCID50*, max. 105.1 TCID50*
* Tissue culture infectious dose – 50%
Diluent (suspension of inactivated vaccine against leptospirosis)
Leptospira icterohaemorrhagiae, strain MSLB 1089 GMT** ≥ 1:51 ALR***
Leptospira canicola, strain MSLB 1090 GMT** ≥ 1:51 ALR***
Leptospira grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 ALR***
Leptospira bratislava, strain MSLB 1088 GMT** ≥ 1:51 ALR***
* Tissue culture infectious dose – 50%
** Geometric mean titre
*** Antibody micro agglutination-lytic reaction
TARGET SPECIES ANIMAL: Dogs
INDICATIONS WITH SPECIFICATION FOR THE TARGET ANIMAL SPECIES:
Active immunization of dogs from 6 weeks of age:
· to prevent mortality and clinical signs caused by canine distemper virus
· to prevent mortality and clinical signs caused by canine adenovirus type 1
· to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
· to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus
· to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus
· to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava
· to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterhaemorrhagiae serovar Icterohaemorrhagiae
· to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa
PACKAGING: 10x1dose, 25x1dose
